Article
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
Brain tumor pathology - 1 Apr 2013
Motegi Hiroaki, Kamoshima Yuuta, Terasaka Shunsuke, Kobayashi Hiroyuki, Yamaguchi Shigeru, Tanino Mishie, Murata Junichi, Houkin Kiyohiro
Abstract excerpt
The purpose of this study was to distinguish pseudoprogression (PP) from early true progression in patients with glioblastoma (GBM) based on the presence of a mutation in isocitrate dehydrogenase 1 (IDH1). We retrospectively surveyed 32 patients with GBM or GBM with oligodendroglioma component (G...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.